ANIK

25.50

2.22% -0.58

Dopo l'orario di chiusura: 25.50

Anika Therapeutics Inc. (ANIK)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$26.08

Aprire:

$26.2

Volume 24 ore:

34,060

Capitalizzazione di mercato:

$378.13M

Reddito:

$166.66M

Utile/perdita netta:

$-82.67M

Rapporto P/E:

-16.67

EPS:

-1.53

Flusso di cassa netto:

$-7.22M

1 W Prestazione:

+0.95%

1M Prestazione:

-0.04%

6M Prestazione:

+21.78%

1 anno Prestazione:

+0.08%

Intervallo 1D:

$25.50

$26.27

Portata 52W:

$16.54

$28.67

Anika Therapeutics Inc. Stock (ANIK) Company Profile

Nome

Anika Therapeutics Inc.

Settore

Healthcare (1211)

Industria

Medical Instruments & Supplies (60)

Telefono

781-457-9000

Indirizzo

32 Wiggins Avenue, Bedford, MA

Dipendente

123

Cinguettio

Prossima data di guadagno

2024-06-13

Ultimi documenti SEC

ANIK's Discussions on Twitter

Anika Therapeutics Inc. Stock (ANIK) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-03-07	Downgrade	Barrington Research	Outperform → Mkt Perform
2022-11-09	Aggiornamento	Barrington Research	Mkt Perform → Outperform
2022-10-14	Ripresa	Stephens	Equal-Weight
2022-03-09	Downgrade	Barrington Research	Outperform → Mkt Perform
2022-03-09	Downgrade	Stephens	Overweight → Equal-Weight
2021-11-16	Iniziato	Stephens	Overweight
2021-07-16	Iniziato	UBS	Neutral
2020-12-16	Aggiornamento	Barrington Research	Mkt Perform → Outperform
2020-05-08	Downgrade	Barrington Research	Outperform → Mkt Perform
2020-01-21	Aggiornamento	Sidoti	Neutral → Buy
2020-01-10	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2019-11-05	Iniziato	BWS Financial	Sell
2019-09-24	Reiterato	Barrington Research	Outperform
2019-09-23	Downgrade	First Analysis Sec	Strong Buy → Outperform
2019-07-25	Aggiornamento	First Analysis Sec	Neutral → Strong Buy
2019-02-22	Downgrade	First Analysis Sec	Outperform → Neutral
2019-02-22	Downgrade	Sidoti	Buy → Neutral
2018-07-27	Aggiornamento	Barrington Research	Mkt Perform → Outperform
2018-06-20	Downgrade	Barrington Research	Outperform → Mkt Perform
2018-06-20	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2018-05-04	Aggiornamento	Barrington Research	Mkt Perform → Outperform
2018-02-23	Downgrade	Barrington Research	Outperform → Mkt Perform
2018-01-24	Aggiornamento	First Analysis Sec	Equal-Weight → Overweight
2017-10-27	Reiterato	Barrington Research	Outperform
2016-05-09	Aggiornamento	Singular Research	BUY - Long-Term → Buy
2016-04-27	Downgrade	Northland Capital	Outperform → Market Perform
2016-02-26	Reiterato	Barrington Research	Outperform

Mostra tutto

Anika Therapeutics Inc. Borsa (ANIK) Ultime notizie

Pendopharm renews distribution agreement with Anika Therapeutics Inc. for Cingal®, Monovisc®, and Orthovisc® - Canada NewsWire

Canada NewsWire

Why You Shouldn't Bet Against Anika Therapeutics (ANIK) Stock? - Yahoo News UK

Yahoo News UK

Research Analysts Set Expectations for Anika Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ANIK) - MarketBeat

MarketBeat

Anika Therapeutics (NASDAQ:ANIK) Receives Outperform Rating from Barrington Research - Defense World

Defense World

Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 52% over the last five years - Yahoo Lifestyle UK

Yahoo Lifestyle UK

New Report Orthopedic Regenerative Medicine Market|Ortho Regenerative Technologies Inc, Personalized stem cells ... - Motions Online

Motions Online

Anika Therapeutics Inc. Azioni (ANIK) Dati Finanziari

Anika Therapeutics Inc. (ANIK) Reddito 2024

ANIK ha riportato un ricavo (TTM) di $166.66 milioni per il trimestre terminato il 2023-12-31, un +6.67% salita anno su anno.

Anika Therapeutics Inc. (ANIK) Reddito netto 2024

ANIK l'utile netto (TTM) è stato di -$82.67 milioni per il trimestre terminato il 2023-12-31, un -456.34% diminuire anno su anno.

Anika Therapeutics Inc. (ANIK) Flusso di cassa 2024

ANIK ha registrato un flusso di cassa disponibile (TTM) di -$7.21 milioni per il trimestre conclusosi con 2023-12-31, un -134.48% diminuire anno su anno.